but the choice of subsequent treatment is still controversial. 4, 5 One approach is continuation of salvage chemotherapy. In large studies published, chemotherapy resulted In the BFM Relapse Study registry we retrospectively identified 136 patients with a first marrow relapse who in an event-free survival (EFS) of 20-30%, 6, 7 in some trials as high as 35%. 8, 9 The main determinants of the outcome had undergone BMT in second complete remission (CR2) (group A) and 33 patients who received transof chemotherapy, as well as bone marrow transplantation (BMT), are duration of the first remission, site of relapse, plants only after a 2nd bone marrow (BM) relapse had occurred (group B). Event-free survival (EFS) rates at and phenotype of leukemic cells. 9-13 Allogeneic BMT is an alternative treatment for children in second CR. However, 6 years after BMT were 0.49 ± 0.05 and 0.48 ± 0.09 for patients transplanted in CR2 and CR3, respectively. In related compatible donors are only available for 15-25% of children. In large series, EFS rates of 40-55% after allocontext with the BFM chemotherapy trials for relapsed childhood ALL there is a clear benefit from BMT in 2nd geneic BMT in 2nd CR have been reported. 11,14-16 Low relapse rates following BMT are purchased at the expense CR for children with unfavorable prognostic features (isolated early BM relapse, very early BM relapse or of serious therapy-related acute complications and late effects, relating to toxicity of conditioning chemotherapy BM relapse of T cell ALL). Similar control of leukemia can be achieved with either chemotherapy or BMT in and radiation, graft-versus-host disease, infections including interstitial pneumonia, immune deficiency, and second late BM relapse of ALL. Assuming a 60% failure rate with chemotherapy for patients in second relapse, a malignancies. To our knowledge there are few corresponding reports on late effects after several courses of chemothird remission can be achieved in about 60% of patients who have received chemotherapy, rendering therapy. [17][18][19][20] Thus, the question arises, if withholding BMT in CR2 and carrying out BMT only after a second bone them eligible for BMT in 3rd CR. With this strategy 58% of these patients would survive and late sequelae marrow relapse occurs is a possible alternative compared to BMT immediately after attaining second remission. This of BMT be restricted to a minority. To withhold BMT in CR2 and not perform BMT before a 2nd BM relapse question is especially interesting for children with late marrow relapse without a related donor. We therefore perforhas occurred, may be a conceivable alternative for children with late ALL BM relapse, at least if no related med a retrospective analysis with the aim of comparing results of BMT in second CR with those obtained with donor is available. Keywords: children; acute lymphoblastic leukemia; bone BMT in third CR. Additionally, known risk factors predictive for the occurrence of a subsequent relapse were taken marrow relapse; allogeneic bone marrow transplantation into consideration.
Over the past three decades, great advances have been
Patients and methods made in the treatment of children with acute lymphoblastic leukemia (ALL): 30 years ago more than 90% of children Between April 1983 and June 1995, children and adodied of this disease; nowadays, conventional chemotherapy lescents with relapsed non-B ALL were enrolled in four regimens achieve high complete remission (CR) rates of consecutive multicenter trials of the BFM (Berlin-Frank-90-100% and long-term remission rates of up to 70% or furt-Münster) Relapse Study Group. 169 patients up to 19 more. [1] [2] [3] In about 30% of patients the disease recurs. Most years of age, grafted from related donors after bone marrow of these children attain a second CR with chemotherapy, relapse of ALL, were registered in the BFM trials. BMT was performed in complete remission after first relapse in 136 children and after second relapse in 33 children. Diag-apy. Very early relapses were defined as those that occurred months (range 2-79 months). Eighty of 136 patients (59%) had either early (32%) or very early (27%) relapses. after less than 18 months of first remission duration.
The following guidelines for alloBMT have been proMedian time between diagnosis of relapse and BMT was 129 (57-481) days. This wide range of time between posed by the BFM study group. Matched related BMT has been a firm constituent of the relapse protocol and was recrelapse and transplantation, 2 to 16 months, was mainly due to therapy-related complications which led to postommended for all patients with first or subsequent BM relapse except for those having experienced a relapse ponement of BMT. Sites of relapse were isolated bone marrow (BM) in 100 patients, BM plus CNS in 18, BM plus beyond 4 years of first remission duration. For these patients BMT was optional. After detailed information to testis in 13, BM plus other sites in four and BM plus CNS plus other sites in one patient. There was a preponderance patients and parents had been given by the physician responsible, decisions about transplantation were made in of boys (86 of 136, 63%). The distribution of immunological subtypes was B precursor-ALL (n = 119) and T cell agreement with the individual treatment center. Ninety percent (152 of 169) of the patients transplanted had initially ALL (n = 12). Five patients were not classified. In the majority of patients (n = 127) conditioning regimens prior been treated according to BFM 3, 21, 22 (10) 3 (9) pendent significant risk factors (time of relapse, site of relapse and immunophenotype) were analyzed for their impact on the prognosis of the patients. A comparison of and 0.50 ± 0.18 for early relapsed patients, whereas the EFS rate for late relapsed patients was 0.61 ± 0.14. both strategy groups is summarized in Table 2 .
For the different sites of relapse EFS rates were 0.46 ± 0.10 for 26 patients with isolated BM relapse, comPatients transplanted in second CR (strategy A) pared to 0.51 ± 0.20 for seven patients with combined BM relapse. Only one out of four children with T cell ALL is With a median follow-up of 63 months (2-140) from BMT, the cumulative proportion of the entire cohort of patients in CR. The EFS-rate in ALL with B precursor phenotype was 0.55 ± 0.10 ( Table 2) . receiving BMT in CR2 surviving without event at 6 years is 0.49 ± 0.05. Seventy-one of these 136 patients treated for first relapse are in continuous CR and still under obser-
Comparison of patients transplanted in second vs third vation. One child was lost to follow-up in second CR dur-CR ing the course of the study. The toxic death rate related to There was no statistically significant difference between transplantation was 13% (18 of 136). Forty-six (34%) of the patients grafted in second or third remission in terms of patients suffered a subsequent relapse. Thirty-four (74%) of EFS or relapse rate. The corresponding EFS at 6 years was the 46 patients who subsequently relapsed died.
0.49 ± 0.05 for 136 children transplanted for first relapse, The 6-year estimates for EFS were 0.31 ± 0.08 for very not significantly different from 0.48 ± 0.09 for the 33 early and 0.60 ± 0.08 for early relapse patients, whereas the patients treated for second relapse (P = 0.815, Figure 1 ). EFS rate for late relapse patients was 0.53 ± 0.07. In 100 patients with isolated BM relapse the 6-year EFS-rate was 0.49 ± 0.05, compared to 0.49 ± 0.09 for 36 patients with Discussion combined BM relapse. The poorest outcome was seen in Data obtained from this retrospective analysis indicate that 12 children with T cell ALL; EFS-rate at 6 years was only the probability of EFS may be comparable for bone marrow 0.25 ± 0.12. EFS-rate in ALL with the B precursor phenotype was 0.51 ± 0.05 (Table 2) .
Patients transplanted in CR3 (strategy B)
After a median follow-up of 44 months (4-134 months) from BMT, 16 of the 33 transplanted patients are in 3rd CCR. One patient was in CCR 6 years after BMT but subsequently suffered a second malignancy. The estimated EFS at 6 years is 0.48 ± 0.09 for the entire cohort. The toxic death rate related to transplantation was 30% (10 of 33). Six children suffered a relapse within 740 (median for EFS after second relapse were 0.27 ± 0.16 for very early 33, 34 In addition, there is a substantial risk for the occurrence of a second after ALL marrow relapse. This is in contrast to earlier published data, suggesting only 15% leukemia-free survival malignancy after BMT, estimated to be 9.9% at 13 years according to a recent report. 35 at 3-5 years following BMT in third remission. 26, 27 In general, allogeneic BMT is recommended as the treatIn the BFM relapse studies 986 patients were registered for first relapse of ALL and received conventional chemoment of choice after relapse of ALL if a suitable related donor is available. Data published in this context show EFS therapy. 782 attained a 2nd CR. Second malignant neoplasms occurred in two of these patients after 25 and 27 rates for BMT in CR2 of 40-60%. 7, 14, 28, 29 Our group has recommended allogeneic related donor BMT for patients months, and 233 patients are still in 2nd CR after a median observation time of 6 years. Thus, the occurrence of a with early marrow relapse. With BMT the results were not different between late and early relapses, indicating that the second malignancy after conventional chemotherapy was below 1% at 6 years. latter group clearly benefits from BMT. 11, 30 However, at that time data on results of BMT in third remission were Hence, there may be some reason for withholding BMT in 2nd CR from patients with late bone marrow relapse in lacking.
In recent reports it has been shown that EFS rates with whom statistically similar control of leukemia can be achieved with chemotherapy, at least if no related donor can BMT in 3rd CR were in the range of 40-45%, 28, 31 somewhat inferior as compared to the results obtained in our 33 be found. Following this strategy, according to our data the overall retrospectively analyzed patients. However, in agreement with earlier reports this article is one more to demonstrate survival rate would not be reduced. If a patient fails after BMT, success with a second BMT may not be impossible that a substantial proportion of children with relapsed ALL can be cured even after BMT in 3rd CR.
but is rather unlikely. If a patient fails after chemotherapy for late isolated marrow relapse, the chance of obtaining a The present article differs from previous reports in two major aspects: (1) patients analyzed here have been treated 3rd CR is 60%. Based on a 60% failure rate, 36% of this patient population would be eligible for BMT in 3rd CR, within controlled multicenter trials and have thus received uniform chemotherapy for second remission induction and with a 50% chance of success. Thus, the overall survival would be about 58% and late sequelae of BMT would be consolidation prior to transplant; in addition, the intensity of front-line therapy was comparable, because more than restricted to a minority of children ( Figure 2 ). In summary, once relapse has occurred in a child with 90% of children had initially been treated according to BFM or CoALL protocols. (2) Aside from the number of ALL, the individual situation has to be carefully considered. Although allogeneic BMT from related donors can previous relapses additional factors determining the prognosis after relapse, eg site and time of relapse and immunobe managed with tolerable toxicity it may not be the best treatment for all children in 2nd bone marrow remission. phenotype of leukemic cells, were taken into account. Duration of first CR was different between the two groups, but Unrelated donor BMT should be considered with caution since matched unrelated donor BMT with an outcome of as shown by Dopfer et al, 11 with allogeneic BMT the results are similar between late and early relapses. However, first about 40% survival in the situation of first relapse is associated with substantial morbidity and mortality. remission duration is a critical factor in other studies. Therefore, the results have to be regarded in context with We feel that the data and issues presented here justify a properly designed prospective randomised study comparing the results of the BFM relapse trials in general. These have shown that children with early isolated marrow relapse or alloBMT in CR2 with chemotherapy in CR2 plus, if necessary, BMT in CR3 in children with late ALL bone marrow very early marrow relapse or relapse of T cell ALL have a very unfavorable prognosis when treated with conventional relapse. An answer to this question is very important in view of the increasing demand for unrelated donor BMT. chemotherapy. 9 These patients have a much lower remission rate as compared to others and their chance of EFS is almost zero. Therefore, immediate BMT is unequivocally indicated in this subset of patients as soon as a 2nd remission has been achieved, and, in face of the dismal prognosis, BMT from unrelated donors should be performed if a suitable donor can be found in time.
In contrast, children with late marrow relapse were shown to have DFS rates of about 40% with chemotherapy. 9, 13, 32 These figures are similar to the results obtained with BMT in CR2. However, assuming a similar success and failure rate with both treatments, the choice of treatment must consider acute and long-term toxicity of Once a remission has been achieved, the treatmentlate bone marrow relapse and corresponding outcomes. Strategy A CCR rate with BMT in second CR is about 50%. Strategy B 40% of the children related mortality with further chemotherapy is almost zero reach a 2nd CCR by chemotherapy after first relapse and 60% fail.
whereas lethal complications with allogeneic BMT are still
Additional induction results in 60% CR rate (=36% of the initial in the range of 5-10%. Likewise, morbidity with chemopopulation). BMT in CR3 results in 50% CCR rate (=18% of the initial therapy is low, but long-term sequelae after BMT such as population). Cumulative CCR rate of delaying BMT until 3rd CR is 58% (40 + 18%).
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